symdeko beat triplerx phase iii enrol rapidli nda
cf sale million beat million estim driven strong symdeko
uptak orkambi cannib symdeko sale million
orkambi million kalydeco sale strong million vertex
increas cf sale guidanc billion billion
forecast billion non-gaap dilut ep beat vertex hold cash
billion importantli triplerx phase enrol rapid vertex anticip file
nda best regimen approv like await updat
partner crispr file beta-thalassemia europ sickl cell diseas
ind reiter overweight increas target roll
discount period includ impact nol benefit unchang
multipl appli increas non-gaap ep discount
thru price target includ
impact one-tim nol benefit expect
symdeko launch drive fda approv symdeko treat cf patient
year homozyog residu function mutat februari
price wac repres slight premium orkambi sale
million driven patient receiv prior cftr modul
therapi homozyg patient discontinu orkambi estim
 patient elig symdeko today includ residu function
patient kalydeco label expans weak orkambi sale million
signal cannib symdeko kalydeco sale million in-lin total
cf franchis remain strong sale million beat estim
street result vertex increas cf sale guidanc billion
billion forecast billion year anticip
symdeko european approv well kalydeco orkambi label
expans pdufa date set august continu drive cf sale growth
year
triplerx enrol ahead schedul nda target enrol four
phase trial plu symdeko het/min homozyg
patient ahead schedul expect complet vertex intend
file nda base efficaci safeti data
believ favor regulatori path aid rapid consist
improv phase ii studi could result approv first cf triplerx
regimen
continu page
cf drug may fail clinic gain approv may meet expect
vertex biopharmaceut compani develop innov drug
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
crispr develop may fda place clinic hold ind applic
sickl cell diseas scd maintain belief hold like reflect
fda question regard manufactur and/or plan monitor safeti understand crispr
receiv written feedback fda respond due cours believ
similar issu delay cta review europ one clear beta-
thalassemia continu expect phase i/ii start beta thal year
potenti scd upon resolut fda clinic hold
page
good sold
royalti payment
thousand except per share data
net incom loss attribut allio
compani report piper jaffray co analysi
current disclosur inform compani found http //www piperjaffray com/researchdisclosur
